一名接受芬戈莫德治疗的多发性硬化症患者发生胶质母细胞瘤：因果关联还是偶然关联？ - Suppr | 超能文献

相似文献

1

Glioblastoma in a fingolimod-treated multiple sclerosis patient: Causal or coincidental association?一名接受芬戈莫德治疗的多发性硬化症患者发生胶质母细胞瘤：因果关联还是偶然关联？

Mult Scler Relat Disord. 2020 Jun;41:102012. doi: 10.1016/j.msard.2020.102012. Epub 2020 Feb 15.

2

Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.在用芬戈莫德治疗复发缓解型多发性硬化症后发生的胶质母细胞瘤。

J Clin Neurosci. 2016 Aug;30:166-168. doi: 10.1016/j.jocn.2016.02.003. Epub 2016 Mar 9.

3

Fingolimod-induced immune thrombocytopenic purpura (ITP).芬戈莫德诱发的免疫性血小板减少性紫癜（ITP）。

Clin Neurol Neurosurg. 2020 Oct;197:106081. doi: 10.1016/j.clineuro.2020.106081. Epub 2020 Jul 10.

4

Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.鞘氨醇 1-磷酸受体调节剂在多发性硬化症治疗中的应用：实践综述。

Ann Clin Transl Neurol. 2024 Apr;11(4):842-855. doi: 10.1002/acn3.52017. Epub 2024 Feb 16.

5

Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.在多发性硬化症中，通过在不同的1-磷酸鞘氨醇受体调节剂之间切换，能否优化治疗不良事件？一项病例系列研究。

J Neurol. 2024 Jun;271(6):3678-3681. doi: 10.1007/s00415-024-12342-z. Epub 2024 Apr 2.

6

Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.鞘氨醇-1-磷酸受体调节剂在复发缓解型和继发进展型多发性硬化中的获益-风险特征。

Drugs. 2017 Oct;77(16):1755-1768. doi: 10.1007/s40265-017-0814-1.

7

Cytomegalovirus Encephalitis Under Fingolimod Mimicking Progressive Multifocal Leukoencephalopathy?芬戈莫德治疗下的巨细胞病毒性脑炎酷似进行性多灶性白质脑病？

Neurol Neuroimmunol Neuroinflamm. 2021 Apr 9;8(4). doi: 10.1212/NXI.0000000000000996. Print 2021 Jul.

8

Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis.芬戈莫德治疗多发性硬化症的临床前发现和开发。

Expert Opin Drug Discov. 2019 Nov;14(11):1199-1212. doi: 10.1080/17460441.2019.1646244. Epub 2019 Aug 7.

9

Fingolimod-Associated Intracerebral Lymphoproliferative Disorder.芬戈莫德相关脑内淋巴组织增生性疾病。

Am J Ther. 2019 Jul/Aug;26(4):e481-e484. doi: 10.1097/MJT.0000000000000694.

10

[Translated article] Risk of Skin Cancer Associated with Disease-Modifying Therapies in Multiple Sclerosis: A Comprehensive Evidence Review.[译文] 多发性硬化症疾病修正疗法相关皮肤癌风险：全面证据回顾。

Actas Dermosifiliogr. 2024 Sep;115(8):T781-T790. doi: 10.1016/j.ad.2024.07.007. Epub 2024 Jul 5.

引用本文的文献

1

Glioblastoma in Patients With Multiple Sclerosis.多发性硬化症患者中的胶质母细胞瘤

Neurohospitalist. 2022 Oct;12(4):607-616. doi: 10.1177/19418744221106003. Epub 2022 Jun 8.

2

Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management.同时患有中枢神经系统肿瘤和多发性硬化症：回顾性单中心队列研究及对临床管理的启示。

Neurol Sci. 2022 Sep;43(9):5513-5522. doi: 10.1007/s10072-022-06142-4. Epub 2022 May 19.

3

First Report of Tumor Treating Fields (TTFields) Therapy for Glioblastoma in Comorbidity with Multiple Sclerosis.